Perceptive Advisors’s Trillium Therapeutics TRIL Stock Holding History
Bought
Maintained
Sold
Other funds holding TRIL
Perceptive Advisors's TRIL Position: Q4 2020 in Review
Perceptive Advisors sold out of Trillium Therapeutics (TRIL) in Q4 2020, closing a stake of 114,674 shares — an estimated $1.63M sold.
Perceptive Advisors first reported a position in TRIL in Q2 2015 and held it in 6 quarters. The position peaked at $1.63M in Q3 2020. 131 funds tracked by Wall St. Rank hold TRIL as of Q4 2020.
- Perceptive Advisors reported no remaining Trillium Therapeutics position as of Q4 2020 after selling out during the quarter.
- Perceptive Advisors sold 114,674 Trillium Therapeutics shares in Q4 2020, an estimated $1.63M.
- Perceptive Advisors first reported a position in Trillium Therapeutics in Q2 2015 and held it in 6 quarters.
- Perceptive Advisors's Trillium Therapeutics position peaked at $1.63M in Q3 2020.
- 131 funds tracked by Wall St. Rank held Trillium Therapeutics as of Q4 2020.
Based on Perceptive Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.